Seeking Alpha

Bad news for Orexigen (OREX -38%) and its Contrave obesity drug: Regulators "requested a...

Bad news for Orexigen (OREX -38%) and its Contrave obesity drug: Regulators "requested a pre-approval cardiovascular outcomes trial that OREX believes is unprecedented and would generate significantly more information than is necessary or feasible." Regulators also won't consider approving Contrave for a narrowed population without first reviewing data from the trial. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs